Gaetan des Guetz

Learn More
Anti-angiogenic targeted therapies are now major tools in the management of solid tumors. Briefly, one can distinguish between monoclonal antibodies such as bevacizumab directed against vascular endothelial growth factor (VEGF) and small molecules such as those targeted against receptors with tyrosine-kinase activity. Soon after they were marketed, these(More)
OBJECTIVE About 15% of colorectal adenocarcinomas have a deficient DNA mismatch repair phenotype. The frequency of deficient DNA mismatch repair tumours increases with age due to the hypermethylation of hMLH1 promoter. The study aimed to determine the prognostic value of deficient DNA mismatch repair phenotype in elderly patients. DESIGN Mismatch repair(More)
Angiogenesis inhibitor drugs (bevacizumab, sunitinib, sorafenib, etc.) are now widely used for treatment of cancers, including colorectal, advanced renal-cell and hepatocellular carcinomas, breast cancer). Vascular and renal side-effects of the drugs are not well known. Hypertension is one of the most common side effects. Incidence of hypertension may be(More)
Tyrosine-kinase inhibitors (TKIs) markedly improve progression-free survival (PFS) of patients with advanced non-small-cell lung cancer (NSCLC) mutated for epidermal growth factor receptor (EGFR). Results on overall survival (OS) are less clear-cut. We performed a publication-based meta-analysis to address further this issue. We did a PubMed query using(More)
A specific treatment for gastrointestinal stromal tumors (GIST) has been found through improved understanding of the molecular mechanism of carcinogenesis. GIST are radio and chemo-resistant (less than 10 objective responses). Stromal tumors originate from the multiplication of the cells of Cajal, which intervene in intestinal motility and express the c-Kit(More)
Pour les patients opérés d’un cancer du côlon ou du rectum et ayant une stomie, celle-ci représente toujours une contrainte. La stomie est cependant nécessaire et indispensable lors d’une occlusion opérée en urgence par exemple. Elle peut malheureusement être définitive, lorsque le cancer est situétrès bas au niveau du rectum. Cela est cependant rare(More)
The area of biological and targeted therapies exploded in the late 1990s. After obtaining good results in hematological malignancies, cancer treatment is now being based on monoclonal antibodies. ASCO has integrated various areas of biological therapy into its scope of clinical activity. Trastuzumab (Heceptin) and bevacizumab (Avastin), antibodies targeting(More)
La chirurgie a été considérée comme le traitement standard du cancer bronchique non à petites cellules opérable (CBNPC). Cependant, en dépit d’une chirurgie optimale, la survie à 5 ans est médiocre, avec près de la moitié des patients rechutant et décédant. La méta-analyse publiée en 1995 montrait un bénéfice pour les patients traités par une chimiothérapie(More)
The clinical benefit of first-line doublet chemotherapy (including oxaliplatin or irinotecan) compared to single-drug therapy (5FU) in elderly patients (>70 or >75 years old) with metastatic colorectal cancer (MCRC) is controversial. Therefore, we undertook a meta-analysis of all published phase III studies. We performed a PubMed search using keywords(More)
Digestive cancers are frequent in elderly patients. However, there are few specific studies on treatment in elderly patients. Selection of the patient is basic to apply the treatment validated in younger patient. Adaptation of the treatment to each case should be done in a multidisciplinary team with a geriatrician. Les cancers digestifs sont fréquents chez(More)
  • 1